Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001600620-25-000092
Filing Date
2025-07-31
Accepted
2025-07-31 06:10:28
Documents
63
Period of Report
2025-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q auph-20250630.htm   iXBRL 10-Q 932620
2 EX-31.1 auph-2025q2exx311.htm EX-31.1 10708
3 EX-31.2 auph-2025q2exx312.htm EX-31.2 10845
4 EX-32.1 auph-2025q2exx321.htm EX-32.1 5255
5 EX-32.2 auph-2025q2exx322.htm EX-32.2 5263
  Complete submission text file 0001600620-25-000092.txt   5310489

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT auph-20250630.xsd EX-101.SCH 30418
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT auph-20250630_cal.xml EX-101.CAL 69999
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT auph-20250630_def.xml EX-101.DEF 145623
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT auph-20250630_lab.xml EX-101.LAB 525291
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT auph-20250630_pre.xml EX-101.PRE 348034
65 EXTRACTED XBRL INSTANCE DOCUMENT auph-20250630_htm.xml XML 669381
Mailing Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6
Business Address #140, 14315 - 118 AVENUE EDMONTON A0 T5L 4S6 250-744-2487
Aurinia Pharmaceuticals Inc. (Filer) CIK: 0001600620 (see all company filings)

EIN.: 981231763 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36421 | Film No.: 251169168
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)